Table 2 Characteristics of the 35 patients with both pre- and post-CCRT specimens.
Patient characteristic | Total (%) (N = 35) |
|---|---|
Age (years) | |
Mean (SD) | 62.6 (10.3) |
Sex | |
male | 28 (80) |
Smoking status | |
never-smoker | 5 (14) |
current or former smoker | 30 (86) |
Histology | |
adenocarcinoma | 16 (46) |
squamous | 18 (51) |
others | 1 (3) |
Stage | |
II A | 6 (17) |
II B | 8 (23) |
III A | 20 (57) |
III B | 1 (3) |
ECOG-PS | |
0 | 26 (74) |
1 | 9 (26) |
Chemo-radiotherapy regimen | |
Vinorelbine plus platinum | 25 (71) |
Docetaxel plus platinum | 5 (14) |
Paclitaxel plus platinum | 3 (9) |
S1 plus platinum | 1 (3) |
Pemetrexed plus platinum | 1 (3) |
Radiotherapy dose | |
40Gy | 31 (89) |
50Gy | 4 (11) |
Down staging * | |
Yes | 22 (63) |
No | 13 (37) |
PD-L1 status on tumor cells before CCRT | |
positive | 22 (63) |
negative | 13 (37) |
PD-L1 status on tumor cells after CCRT** | |
positive | 21 (60) |
negative | 14 (40) |
Change in PD-L1 expression level on tumor cells after CCRT ** | |
increased | 4 (11) |
unchanged | 15 (43) |
decreased | 16 (46) |
CD8+ lymphocytes density before CCRT*** | |
high | 0 (0) |
intermediate | 10 (29) |
low | 24 (71) |
CD8+ lymphocytes density after CCRT ** | |
high | 3 (9) |
intermediate | 20 (57) |
low | 12 (34) |
Change in CD8+ lymphocytes density after CCRT **** | |
increased | 17 (50) |
unchanged | 16 (47) |
decreased | 1 (3) |
